CG Oncology, Inc. (CGON)
74.67
+0.34
(+0.46%)
USD |
NASDAQ |
Sep 04, 16:00
74.64
-0.03
(-0.04%)
After-Hours: 20:00
CG Oncology Debt to Equity Ratio : 0.0086 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.0086 |
| March 31, 2026 | 0.0069 |
| December 31, 2025 | 0.0093 |
| September 30, 2025 | 0.0105 |
| June 30, 2025 | 0.0015 |
| March 31, 2025 | 0.0015 |
| December 31, 2024 | 0.0003 |
| September 30, 2024 | 0.0006 |
| Date | Value |
|---|---|
| June 30, 2024 | 0.0006 |
| March 31, 2024 | 0.0007 |
| December 31, 2023 | 0.0045 |
| September 30, 2023 | 0.0045 |
| June 30, 2023 | |
| March 31, 2023 | |
| December 31, 2022 | 0.1302 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Tyra Biosciences, Inc. | 0.0158 |
| Arrowhead Pharmaceuticals, Inc. | 2.956 |
| Oncolytics Biotech, Inc. | -0.0726 |
| Sangamo Therapeutics, Inc. | -1.020 |
| Sarepta Therapeutics, Inc. | 0.6845 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 1.086B |
| Total Liabilities (Quarterly) | 56.54M |
| Shareholders Equity (Quarterly) | 1.029B |
| Current Ratio | 22.22 |
| Net Debt Paydown Yield | -0.02% |